Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-016-4080-9.pdf
Reference30 articles.
1. Miller K, Sledge G (1999) The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 13(2):416–443
2. Sant M, Allemani C et al (2004) Breast carcinoma survival in Europe and the United States. Cancer 100(4):715–722
3. Early Breast Cancer Trialists’ Collaborative Group (2005) (EBCTCG): effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365(9472):1687–1717
4. Metzger-Filho O et al (2013) Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from the international breast cancer study group trials VIII and IX. J Clin Onc 31(25):3083–3090
5. Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277
Cited by 142 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Radiation therapy of the primary tumour and oligometastatic sites in patients with breast cancer with synchronous metastases: A literature review;Cancer/Radiothérapie;2024-02
2. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives;Nature Reviews Clinical Oncology;2024-01-08
3. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort;European Journal of Cancer;2024-01
4. Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2–Positive Metastatic Breast Cancer in Manitoba;American Journal of Clinical Oncology;2023-12-04
5. Long-chain noncoding RNA LINC01569 upregulates filamin A-interacting protein 1-like to prevent metastasis of triple-negative breast cancer via sponging miR-300;Cancer Biomarkers;2023-10-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3